SEC EDGARNov 12$ARXS

Perhamus Kevin Scott sold $1.3M of ARXS

Perhamus Kevin Scott (See Remarks) sold 25,000 shares of Arxis, Inc. (ARXS) at an average of $50.92 ($50.59–$51.19, $1.27M total) across 2 trades on 2026-11-09.

Original reporting

SEC EDGAR · Perhamus Kevin Scott

Published Nov 12, 2026, 9:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 12, 2026, 9:26 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ARXS

Bearish

medium confidence

Mentioned

$ARXS

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ARXSBearishLow

Why it matters

A 25,000‑share sale by a director may trigger short‑term selling pressure, but the retained stake limits the signal.

Market read

The filing provides new, material information about insider activity that could influence short‑term trading decisions.

What to watch

The insider retains a large stake (over 3.5 M shares) indicating continued confidence.

Relevance 6/10Novelty 4/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ARXSBearishMedium confidence

Context

SEC Form 4 shows officer/director Kevin Scott sold 25,000 shares for $1.27 M, a new insider sale.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Insider sales by senior executives often lead to short-term sell pressure, especially when the transaction size is material relative to float.

Market effects

Sector

Minimal; the sale is company‑specific and does not affect the broader biotech sector.

Regional

None; the filing is US‑based and limited to ARXS shareholders.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

company
Arxis, Inc.
Biotech firm listed on Nasdaq under ticker ARXS.
person
Kevin Scott
Officer and director of Arxis who sold shares.

Read at source ← All news

MedAI 8/10

Arxis Q3 2026 presentation: 67% EBITDA jump, stock falls 10%

Arxis reported Q3 2026 revenue of $564M (+36% YoY) and adjusted EBITDA of $256M (+67% YoY), raising full-year guidance but warning of margin normalization. Shares fell 10% post-earnings, citing concerns over growth sustainability and high valuation. The company plans acquisitions and expects 2027 revenue of $2.4B-$2.5B.

investing.comOct 29

Med

Quarterly profit swung from a $10 million loss to $84 million at Arxis.

Arxis reported Q3 2026 revenue of $564 million, up 36% YoY, with net income of $84 million, compared to a $10 million loss in Q3 2025. Adjusted EBITDA rose 67% to $256 million. The company raised full-year 2026 guidance and introduced 2027 guidance, anticipating continued growth and margin expansion. Recent acquisitions include Omnetics, Schatz Bearing, and StratEdge.

stocktitan.netOct 28

$ARXSMed

RBC Capital upgrades Arxis to Outperform, sets $60 price target

RBC Capital upgraded Arxis to Outperform with a $60 price target, implying 26.3% upside from its Oct 1 close. The firm cited strong M&A execution and resilience in pricing power in the defense sector.

tradingview.comOct 2

$ARXSHigh

RBC Capital upgrades Arxis stock rating on M&A activity, pricing

RBC Capital upgraded Arxis Inc. (NASDAQ:ARXS) to Outperform, raising its price target to $60.00. The firm cited strong M&A activity and pricing strength in aerospace and defense markets. Arxis reported 25% revenue growth to $501 million in Q2 2026, with adjusted EBITDA up 38% to $211 million. The company raised its full-year outlook, reflecting broad-based demand and strategic acquisitions.

investing.comOct 2

$ARXSHighAI 9/10

Arxis (ARXS) Closed an Approximately $770 Million Connector Acquisition. Is its Roll-Up Still Disciplined?

Arxis, Inc. (ARXS) completed the acquisition of Omnetics Connector Corporation for approximately $770 million, issuing 13.35 million Class A shares. The deal is part of Arxis's roll-up strategy, with Omnetics joining its Electronic Components segment. The company's Q2 revenue grew 25% to $500.7 million, with adjusted EBITDA up 38% to $211.5 million. The acquisition's valuation is based on estimated fiscal-2027 adjusted EBITDA, raising questions about its disciplined underwriting.

insidermonkey.comAug 25

$ARXSMedAI 8/10

Arxis Completes the Acquisition of Omnetics Connector Corporation

Arxis, Inc. (NASDAQ: ARXS) said it completed its acquisition of Omnetics Connector Corporation. The deal was based on an agreed enterprise value of about $770 million, with customary closing adjustments. Arxis issued 13,351,964 shares at closing to Omnetics shareholders, about 3.1% of total common stock, subject to lockups. The combined purchase price multiple with a prior MagCanica deal is about 12x FY27 estimated adjusted EBITDA.

prnewswire.comAug 18